Aventis Pharma S.a.

Other

Rhone-poulenc Rorer S.a.

Centre National De La Recherche Scientifique

Transgene S.a.

Institut Gustave Roussy

The United States of America As Represented by the Department of Health

Gencell, S.a.

Gencell Sas

Genopoietic

Michel Perricaudet

Patrice Yeh

Emmanuelle Vigne

Patrice Denefle

Martine Latta

Jacques Mallet

C&eacute;cile Orsini

Leslie Stratford-Perricaudet

Patrick Benoit

Hedi Mohamed Haddada

Edouard Prost

Thierry Ragot

Pierre Tiollais

Axel Kahn

Andrea Pavirani

Fr&eacute;d&eacute;ric Revah

Jean-Jacques Robert

Pascale Briand

Annick Ballay

Wilfried Dalemans

Gildas Le Gal La Salle

Massimo Levredo

Vincent Descamps

Jean-Francedillaois Dedieu

Marc Peschanski

Ronald G Crystal

David Klatzmann

Michael R Hayden

Gennaro Ciliberto

William Vainchenker

Jean-Loup Salzmann

Rocco Savino

Yves Beuzard

Olivier Danos

Jeannette Soria

Marc Abitbol

Philippe Moullier

Claudine Soria

Nadia Naffakh

Christophe Torrent

Jean-Michel Heard

Didier Branellec

He Lu

Isabella Saggio

Yves Legrand

Laurent Feldman

Cecile Orsini

Aude Le Roux

Philippe Horellou

Manuel Lopez

Karim Benihoud

Sandrine Seguret

Jean-Francois Dedieu

Anastasia Lanzi

Paul Roustan

Martin Lee

Bernard Klonjkowski

M E Suzanne Lewis

Paule Opolon

Hédi Mohamed Haddada

Frank Griscelli

Hong Li

Christelle Mabilat

H&eacute;l&egrave;ne Leblois-Prehaud

Martin Schlumberger

Cécile Orsini

Jean-Fran&ccedil;ois Dedieu

Philippe Gabriel Steg

Anne Boland-Auge

The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity.

Adenovirus vaccine vectors

The present invention relates to the field of gene therapy and the treatment of tumors.

Recombinant adenoviruses encoding the specific iodine transporter (NIS)

A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.

Defective recombinant adenoviruses expressing cytokines for antitumor treatment

A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.

Recombinant adenoviruses, use thereof for preparing AAVS, complementary cell line, and pharmaceutical compositions containing said adenoviruses

The invention concerns recombinant viruses comprising a heterologous DNA sequence under the control of expression signals specifically active in tumor cells, and their preparation and use in the treatment and prevention of cancers.

Recombinant adenoviruses for gene therapy in cancers

Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.

Targeted adenovirus vectors for delivery of heterologous genes

Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.

Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same

The present invention concerns defective recombinant adenoviruses containing an inserted gene encoding apolipoproteins, pharmaceutical compositions comprising the adenovirus, and their use for the treatment or prevention of pathologies linked to dyslipoproteinemias.

Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias

The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.

Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain

Non-replicable viral recombinant vectors which are recognizable by muscle cell receptors, and furthermore modified by an inserted nucleic acid coding for a polypeptide sequence to be expressed in the muscle cells, are used to obtain a composition for treating muscle cell diseases or disease which, by virtue of their location in the body are accessible to the production of expression. A method for producing said vectors and their use in pharmaceutical compositions are also described.

Viral recombinant vectors for expression in muscle cells

Recombinant DNA modified by a nucleotide sequence coding for a specific polypeptide sequence whose expression is sought, this recombinant DNA being appropriate to the transformation of eucaryotic cell lines, notably human or animal, the endogenous polymerases of which are susceptible of recognizing the adenovirus promoters. The DNA according to the invention is more particularly characterized by the fact that the said insertion nucleotide sequence is placed under the direct control of the early promoter of the E1A region of the genome of adenovirus.

Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein

Recombinant adenoviruses comprising a heterologous DNA sequence coding for basic blast growth factors (bFGF), preparation and uses thereof for the treatment and/or prevention of neurodegenerative diseases.

Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)

Novel adenovirus-derived viral vectors, the preparation thereof, and the use of such vectors in gene therapy, are disclosed. In particular, defective adenoviruses having a genome that includes a first recombinant DNA containing a therapeutic gene and a second recombinant DNA containing an immunoprotective gene, are disclosed.

Defective adenoviruses including a therapeutic gene and an immunoprotectove gene

The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.

Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors

Growing community of inventors

Ecrosnes, France

Michel Perricaudet